All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
Inhibiting the spliceosome may have clinical benefit to patients with spliceosomal gene mutations. Existing sulfonamide drugs may be able to target certain RNA-binding proteins in spliceosome-mutant AML.